TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05943509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative rehabilitation strategies
Description: Counseling intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care audiology pathway.
Study: NCT04676763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Description: Participants will receive Substance P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Description: Participants will receive Substance P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Participants will receive normal saline as Negative control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Participants will receive normal saline as Negative control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Participants will receive histamine as Positive control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Participants will receive histamine as Positive control
Study: NCT06143046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT06384560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a combination of systemic chemotherapy agents. FOLFIRINOX consists of oxaliplatin at a dose of 85 mg/m2, given as a 2-hour intravenous infusion, immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector. This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks. (The FOLFIRINOX given in the trial is the modified scheme, whereby the fluorouracil bolus at a dose of 400 mg/m2 is omitted and the irinotecan dose reduced to 150 mg/m2).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on five non-consecutive days.
Study: NCT06646289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered sub-retinally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered sub-retinally.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention (Follow-Up assessment)
Description: Participants will not receive any intervention and will undergo follow-up assessment.
Study: NCT06646562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + Rilpivirine LA
Description: Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
Study: NCT04765722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Study: NCT06075537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose
Study: NCT05838378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Package image sorting with pictorial warnings
Description: Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Package image sorting with Surgeon General text-only warnings
Description: Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Package image sorting with FDA text-only warnings
Description: Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
Study: NCT06244771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMC-376
Description: Oral Capsule
Study: NCT05839951

Intervention type: DRUG
Intervention: Regorafenib (BAY73-4506, Stivarga®)
Description: Oral multitargeted kinase inhibitor

Intervention type: DRUG
Intervention: TAS-102 (trifluridine and tipiracil, Lonsurf®)
Description: Oral cytotoxic chemotherapy

Intervention type: DRUG
Intervention: Bevacizumab
Description: VEGFR inhibitor

Intervention type: DRUG
Intervention: Bevacizumab
Description: VEGFR inhibitor

Intervention type: DRUG
Intervention: Bevacizumab
Description: VEGFR inhibitor
Study: NCT06538142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + Restoration with Self-cure Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Self-cure Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.
Study: NCT05641402

Intervention type: OTHER
Group type: OTHER
Intervention: Text messages
Description: Text messages based on behaviour change techniques
Study: NCT05006794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamzetoclax
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacituzumab govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacituzumab govitecan-hziy
Description: Administered intravenously
Study: NCT05634499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
Study: NCT05408845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study: NCT05657691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem™
Description: Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
Study: NCT04893954

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full Spine Radiography
Description: Full Spine Radiography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumbar spine MRI
Description: Lumbar spine MRI
Study: NCT06538857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgery
Description: The location and size of the tumor determine the type of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: The location and size of the tumor determine the type of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01
Description: It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
Study: NCT05304104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
Study: NCT06225297

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention package
Description: Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
Study: NCT04910022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Route of administration: Oral~Commercially available temozolomide
Study: NCT06457685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Intravascular Lithotripsy (Pulse IVL)
Description: The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Study: NCT04775381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive a cholecalciferol supplementation added to a fruit juice.
Study: NCT06179758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: icompanion app
Description: use of the icompanion app as a digital telemonitoring solution
Study: NCT04499924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg given twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg given twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg given twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tucatinib placebo
Description: Given twice daily orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab placebo
Description: IV on Days 1 and 15 of each cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trastuzumab placebo
Description: IV on Days 1 and 15 of each cycle
Study: NCT06489197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab combined with albumin paclitaxel and cisplatin
Description: Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
Study: NCT06485635

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone
Study: NCT05759754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM+ Routine Therapy
Description: The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM+ Routine Therapy
Description: The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Therapy
Description: Patients receive a stable dose of ACEI/ARB drug as a routine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Therapy
Description: Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
Study: NCT05502237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study: NCT04906226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-foot massage
Description: The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
Study: NCT05113680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compassion focused group
Description: Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: emotional competencies
Description: Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
Study: NCT05502237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously